The histone deacetylase inhibitor givinostat (ITF2357) exhibits potent anti-tumor activity against CRLF2-rearranged BCP-ALL.

about

Philadelphia chromosome-like acute lymphoblastic leukemia.SRC/ABL inhibition disrupts CRLF2-driven signaling to induce cell death in B-cell acute lymphoblastic leukemia.

P2860

Q43431904-D366BB58-E777-4D58-9126-95D99B5F234D Q55273917-44DEDA24-A641-436B-9D88-20F93CD5197E

P2860

The histone deacetylase inhibitor givinostat (ITF2357) exhibits potent anti-tumor activity against CRLF2-rearranged BCP-ALL.

Item

http://www.wikidata.org/entity/Q48090552

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

The histone deacetylase inhibi ...... inst CRLF2-rearranged BCP-ALL.

@en

The histone deacetylase inhibitor givinostat

@nl

type

Item

label

The histone deacetylase inhibi ...... inst CRLF2-rearranged BCP-ALL.

@en

The histone deacetylase inhibitor givinostat

@nl

prefLabel

The histone deacetylase inhibi ...... inst CRLF2-rearranged BCP-ALL.

@en

The histone deacetylase inhibitor givinostat

@nl

P1476

The histone deacetylase inhibi ...... inst CRLF2-rearranged BCP-ALL.

@en

P2093

A Biondi

http://www.w3.org/2001/XMLSchema#string

A M Savino

http://www.w3.org/2001/XMLSchema#string

C Bugarin

http://www.w3.org/2001/XMLSchema#string

C Palmi

http://www.w3.org/2001/XMLSchema#string

G Cazzaniga

http://www.w3.org/2001/XMLSchema#string

G Fossati

http://www.w3.org/2001/XMLSchema#string

G Gaipa

http://www.w3.org/2001/XMLSchema#string

G P Nolan

http://www.w3.org/2001/XMLSchema#string

G Te Kronnie

http://www.w3.org/2001/XMLSchema#string

J Sarno

http://www.w3.org/2001/XMLSchema#string

P2860

Effect of mitoxantrone on outcome of children with first relapse of acute lymphoblastic leukaemia (ALL R3): an open-label randomised trial

Mutations and deletions of the TP53 gene predict nonresponse to treatment and poor outcome in first relapse of childhood acute lymphoblastic leukemia.

FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma.

A phase II multiple dose clinical trial of histone deacetylase inhibitor ITF2357 in patients with relapsed or progressive multiple myeloma.

The Jak-STAT pathway: cytokine signalling from the receptor to the nucleus.

Functional screening identifies CRLF2 in precursor B-cell acute lymphoblastic leukemia.

The histone deacetylase inhibitor ITF2357 selectively targets cells bearing mutated JAK2(V617F).

Efficacy of JAK/STAT pathway inhibition in murine xenograft models of early T-cell precursor (ETP) acute lymphoblastic leukemia.

mTOR kinase inhibitors synergize with histone deacetylase inhibitors to kill B-cell acute lymphoblastic leukemia cells.

Genetic resistance to JAK2 enzymatic inhibitors is overcome by HSP90 inhibition

P2888

leu.2017.93

P304

2365-2375

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/LEU.2017.93

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Grazia Fazio

P577

2017-03-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28331226

http://www.w3.org/2001/XMLSchema#string

The histone deacetylase inhibitor givinostat (ITF2357) exhibits potent anti-tumor activity against CRLF2-rearranged BCP-ALL.

about

P2860

P2860

The histone deacetylase inhibitor givinostat (ITF2357) exhibits potent anti-tumor activity against CRLF2-rearranged BCP-ALL.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P698

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P698